fingolimod, Gilenya (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
Fingolimod may decrease heart rate, especially after the first dose. Patients should be observed for signs and symptoms of low heart rate for 6 hours after the first dose. Fingolimod may increase the risk of infections. Signs and symptoms of infection should be monitored during treatment and for two months after discontinuation of treatment. Fingolimod should not be administered to patients who have an infection. Fingolimod may cause inflammation of the eye (uveitis) and other eye problems. Therefore, visual acuity should be checked prior to starting therapy, 3 to 4 months after initiation of therapy, and during routine patient evaluation. Fingolimod has also been associated with difficulty breathing. Fingolimod reduces the white blood cell count, and this effect may last for 2 months after treatment is discontinued.
GENERIC AVAILABLE: No
PREPARATIONS: Capsules: 0.5 mg.
STORAGE: Fingolimod should be stored at room temperature, 15 C - 30 C (59 F - 86 F).
DOSING: The recommended dose is 0.5 mg orally once daily, with or without food. Doses higher than 0.5 mg cause more adverse reactions without providing additional benefit.
Vaccines may be less effective during and up to 2 months after discontinuation of fingolimod treatment. Live attenuated vaccines should not be administered during and for 2 months after fingolimod treatment because of the risk of infection.
When combined with drugs that decrease heart rate (for example, atenolol [Tenormin]) there is an additional 15% reduction of heart rate.
PREGNANCY: Fingolimod has not been adequately studied in pregnant women.
NURSING MOTHERS: It is not known whether fingolimod is secreted in breast milk.
Medically reviewed by Eni Williams, PharmD
Reference: FDA Prescribing Information for Gilenya (fingolimod)
Medically Reviewed by a Doctor on 7/9/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions